Apellis Pharmaceuticals Says US FDA Grants Priority Review to Empaveli Application for Rare Kidney Diseases
I'm PortAI, I can summarize articles.
Apellis Pharmaceuticals announced that the US FDA has accepted its supplemental new drug application for Empaveli, aimed at treating rare kidney diseases C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis. The application is supported by late-stage trial results showing significant reduction in proteinuria and stabilization of kidney function. The FDA granted Priority Review, with a decision expected by July 28.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Trading View The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments